- Advanced search
- Guide to IMMUNOPHARMACOLOGY Portal
Molecular properties generated using the CDK
|Compound class||Synthetic organic|
|ALL-3 | AST-1306 | AST1306|
|Allitinib (AST-1306) is an irreversible inhibitor of the wild-type epidermal growth factor receptor (EGFR) and ErbB2 (HER2) . It also inhibits the mutant EGFRT790M/L858R. Allitinib was designed by Allist Pharmaceuticals to overcome acquired resistance to EGFR inhibitor therapy. It is active in vitro and in vivo.
Allitinib is a 'pseudo' INN, that takes the form of an INN, but has not been submitted to the World Health Organisation for ratification.
|GtoPdb PubChem SID||363894206|
|Search Google for chemical match using the InChIKey||MVZGYPSXNDCANY-UHFFFAOYSA-N|
|Search Google for chemicals with the same backbone||MVZGYPSXNDCANY|
|Search UniChem for chemical match using the InChIKey||MVZGYPSXNDCANY-UHFFFAOYSA-N|
|Search UniChem for chemicals with the same backbone||MVZGYPSXNDCANY|